A bipartisan group of Congressional lawmakers has written to Health and Human Services Secretary Robert F. Kennedy Jr., pressing the Trump administration to compel Eli Lilly to restore federally mandated price breaks to hospitals enrolled in the 340B drug discount program. Lilly cut off those discounts last month to roughly 50 larger hospital systems that had refused to hand over claims data the drugmaker now requires as a condition of participation.
What the 340B Program Is — and What's at Stake
The 340B program is a federal drug discount program that requires pharmaceutical manufacturers to sell medicines at reduced prices to qualifying hospitals. Those discounts are not optional perks; they are obligations under federal law, which is precisely the argument the lawmakers are making against Lilly.
The letter to Kennedy contends that Lilly is failing to comply with federal law by eliminating the price breaks. For the hospitals involved, the commercial impact is direct: losing access to mandatory discounts raises drug acquisition costs, a pressure that falls hardest on institutions that rely on the 340B program to offset the cost of care for vulnerable patients.
How Lilly Justified the Move
Lilly framed the discount cutoff as a compliance measure, not a penalty. The company said it was acting to eliminate what it calls duplicate discounts being paid to hospitals. Earlier this year, Lilly announced a new policy requiring hospitals in the 340B program to submit claims data so the company could verify that no double-discounting was occurring.
By Lilly's own account, approximately 70 percent of 340B-participating hospitals — more than 2,300 in total — had already provided that data before the cutoff took effect. The roughly 1,000 hospitals that had not complied became the pool from which Lilly identified the 50 larger systems it ultimately targeted.
The Political Dimension
The bipartisan nature of the Congressional letter signals that the 340B fight is not sorting neatly along party lines. Lawmakers on both sides of the aisle are pushing a Republican-led administration to intervene against a major pharmaceutical company — an unusual alignment that reflects how broadly hospitals have organized against Lilly's new data-sharing requirement.
What Kennedy and the Department of Health and Human Services decide will set a precedent for whether drugmakers can condition 340B discounts on compliance with self-created data policies. If HHS sides with the hospitals, Lilly would face pressure to reinstate discounts without the claims data it says it needs to prevent duplicate payments. If HHS defers to Lilly, other manufacturers may follow with similar requirements, fundamentally reshaping how the 340B program operates in practice.